Here are relevant reports on : urea-cycle-disorder-ucd-drugs-market
-
Asia Pacific Oligonucleotide Synthesis Market by Product {Drugs [ASO, siRNA], Synthesized Oligos [Product (Primers, Probes), Type (Custom, Predesigned)], Reagents, Equipment}, Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Asia Pacific Oligonucleotide Synthesis market, valued at USD 1.76 billion in 2024, stood at USD 2.08 billion in 2025 and is projected to advance at a resilient CAGR of 18.5% from 2025 to 2030, culminating in a forecasted valuation of USD 4.88 billion by the end of the period. This expansion is driven by increasing demand from therapeutics, diagnostics, and research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
North America Oligonucleotide Synthesis Market by Product [(Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type (Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics)] - Forecast to 2030
The North America Oligonucleotide Synthesis market, valued at US$4.02 billion in 2024, stood at US$4.77 billion in 2025 and is projected to advance at a resilient CAGR of 18.9% from 2025 to 2030, culminating in a forecasted valuation of US$11.34 billion by the end of the period. The market is growing due to the strong demand from therapeutics, diagnostics and research. Pharma and biotech end users require high-purity DNA/RNA oligos for siRNA, antisense, aptamers and guide RNAs for gene editing.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Cancer Supportive Care Drugs Market by Drug Class (G-CSFS, ESAS, Antiemetics, Bisphosphonates, Opioids, Nsaids), Cancer Type (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Other Cancers) - Global Forecast to 2023
Cancer supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. With such side effects, there is preference to use supportive care drugs during cancer treatments. Such factors are expected to drive the cancer supportive care drugs market. However, there are some side effects associated with cancer supportive care drugs which may hinder the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
US General Anesthesia Drugs Market by Route of Administration (Intravenous and Inhalational), End User (Hospitals, Ambulatory Surgery Centers) - Global Forecast to 2025
The global US general anesthesia drugs market in terms of revenue was estimated to be worth $2.0 billion in 2020 and is poised to reach $2.4 billion by 2025, growing at a CAGR of 3.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Age-related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept, Faricimab), Approval Type (Biologic, Biosimilar), Type of AMD, End User - Global Forecast to 2029
The global age-related macular degeneration (AMD) drugs market, valued at US$9.55 billion in 2023, stood at US$10.46 billion in 2024 and is projected to advance at a resilient CAGR of 10.7% from 2024 to 2029, culminating in a forecasted valuation of US$17.37 billion by the end of the period. Factors such as the increase in the prevalence of AMD cases due to the changing lifestyle and dietary habits such as smoking, alcohol consumption, and lack of physical activity, a growing focus on research and development highlighted by steady development and approvals of AMD drugs along with improvements in reimbursement policies providing better and affordable access to therapeutic AMD drugs, supports the growth of this market.
- Published: September 2024
- Price: $ 4950
- TOC Available:
-
Europe Human Microbiome Market by Drug & Supplement (Drugs, Probiotics, Prebiotics, Synbiotics), Disease (Infectious, Gastrointestinal, Endocrine & Metabolic Disease), Type (BCT/FMT, LBP), End User (Hospitals, Clinics, Long-term Care) - Forecast to 2031
The Europe Human Microbiome Market, valued at US$0.22 billion in 2024, stood at US$0.29 billion in 2025 and is projected to advance at a resilient CAGR of 28.6% from 2025 to 2031, culminating in a forecasted valuation of US$1.31 billion by the end of the period. The growth of the Europe human microbiome market is driven by increased awareness of personalized health, the adoption of microbiome-based therapies, and advancements in sequencing technologies and bioinformatics.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023
The global Migrane Drugs market is expected to reach USD 3.96 billion by 2023 from USD 1.95 million in 2018, growing at a CAGR of 15.2%. Increasing awareness about novel therapies, launch of Calcitonin Gene-related Peptide (CGRP), increasing incidence of migraines and launch of new drugs are some of the major factors driving the growth of the global suture anchor market. These driving factors consequence to the rapid adoption of these new drugs, thus propelling the market growth.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) - Global Forecast to 2026
The global cognition enhancement market is expected to grow from USD 23.4 billion in 2021 to USD 38.9 billion by 2026, at a compound annual growth rate (CAGR) of 10.7% during the forecast period.The leading players Eisai Co., Ltd. (Japan), Johnson & Johnson Services, Inc. (US), Biogen Inc. (US), Eli Lilly and Company (US), Nordic Naturals (US), Natrol, LLC (US), Cambridge Cognition Ltd. (UK), and Cogstate Ltd. (US).
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Europe Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics) - Forecast to 2030
The Europe Oligonucleotide Synthesis market, valued at USD 2.68 billion in 2024, stood at USD 3.17 billion in 2025 and is projected to advance at a resilient CAGR of 18.7% from 2025 to 2030, culminating in a forecasted valuation of USD 7.49 billion by the end of the period. The market is growing due to strong demand from therapeutics, diagnostics, and research.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030
The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$26.28 billion by the end of the period.
- Published: June 2025
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
